Positron Corporation (POSC)

[JackStraw]

Positron's Portable Injection System, Tech-Assist Reduced Radiation Exposure by 50%-75%
Tuesday March 3, 10:39 am ET



INDIANAPOLIS--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News), a Cardiac Molecular Imaging Solutions Company, announced today the results from an independent study on radiation exposure of technologists administering FDG. The study was conducted in the Nuclear Medicine Department at Mount Sinai Medical Center in New York, N.Y. by the Director of PET, Ash Rafique. The study compared historic whole body and ring readings using a traditional syringe shield compared to Positron’s Tech-Assist™ device. The results showed a reduction in whole body badge exposure by 50%-75% and ring badge reductions of 40%-55%, compared to previous month’s data.
Positron’s Tech-Assist™ is a heavy duty syringe shield (PIG) mounted on a portable cart system. This system is designed to reduce or limit exposure, heavy lifting injuries and repetitive motion injuries that occur during Nuclear Medicine injection applications. The Tech-Assist™ was designed with the ALARA principles of Time, Distance, and Shielding in mind. The Tech-Assist™ utilizes tungsten for all shielding. The cart enables the user to transport the PIG to and from the injection room with ease and adjusts to various height levels allowing for the injection of ambulatory or supine patients. . The variable injection head rotates 360° allowing for left or right arm injections and hinges to four different angles creating multiple loading or injecting positions. In additional to significant reduction in radiation exposure the Tech-Assist™ will improve the comfort and ease of the injection process for the patient as well as for the technologist/nurse.

About Positron

Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Radiopharmaceutical Products and Molecular Imaging Devices. The Pharmaceutical Products segment offers the world’s first robotic systems (Nuclear Pharm-Assis® & Cardio-Assist™) for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases; the Molecular Imaging Devices segment provides PET scanners (Attrius™) and SPECT cameras (Pulse®);. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.

Forward Looking Statements:

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.




Contact:
Positron Corporation
Joseph Oliverio, [phone]

--------------------------------------------------------------------------------
Source: Positron Corporation